Top

Current Fungal Infection Reports

Published in:

01-12-2020 | Candidiasis | Pediatric Fungal Infections (D Corzo Leon, Section Editor)

Skin Fungal Infections in Children: Diagnostic Challenges

Authors: Maria Teresa García-Romero, Gabriela Sánchez-Cardenas, Silvia Angélica Carmona-Cruz, Mónica Fernández-Sánchez

Published in: Current Fungal Infection Reports | Issue 4/2020

Abstract

Purpose of Review

Children are usually affected by superficial mycoses; however, subcutaneous mycoses are rarer and difficult to diagnose since their presentation, risk factors, epidemiology, and probably pathophysiology sometimes differ from adults. This article provides an updated overview of skin fungal infections affecting children, their clinical manifestations, and practical approaches for a correct diagnosis and management.

Recent Findings

Skin fungal infections in children have increased in number in the last decades. The majority of children suffer from one at least one time during infancy. This is probably the result of changing lifestyles, and immunosuppression (such as HIV, transplants, neoplastic diseases, and iatrogenic immunosuppression).

Summary

Children can suffer from a superficial fungal infection (skin, nails, and hair), which usually is easily diagnosed and amenable to treatment; but subcutaneous fungal infections may cause difficulties in diagnosis and treatment. The incidence rate is increasing at an alarming rate and available treatments should be chosen carefully in order to avoid future resistance.

Hay RJ. Fungal infections. Clin Dermatol. 2006;24(3):201–12. https://doi.org/10.1016/j.clindermatol.2005.11.011.PubMedCrossRef

Arenas R, Moreno-Coutiño G, Welsh O. Classification of subcutaneous and systemic mycoses. Clin Dermatol. 2012;30(4):369–71. https://doi.org/10.1016/j.clindermatol.2011.09.006.PubMedCrossRef

Jain A, Jain S, Rawat S. Emerging fungal infections among children: a review on its clinical manifestations, diagnosis and prevention. J Pharm Bioallied Sci. 2010 Oct;2(4):314–20. https://doi.org/10.4103/0975-7406.72131.PubMedPubMedCentralCrossRef

Walsh TJ, Dixon DM. Spectrum of mycoses. In: Baron S, editor. Medical microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 75. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7902/.

•• Taudorf E, Jemec G, Hay R, Saunte D. Cutaneous candidiasis – an evidence-based review of topical and systemic treatments to inform clinical practice. J Eur Acad Dermatol Venereol. 2019;33(10):1863–73. https://doi.org/10.1111/jdv.15782(This article features an extensive review of available treatments for candidiasis, their effectiveness, comparisons between them, and adverse effects).PubMedCrossRef

Bhai N, Tendolkar U, Baradkar V, Mathur M, Kulkarni M. Paediatric oropharyngeal and cutaneous candidiasis with special reference to Candida dubliniensis. J Med Microbiol. 2014;63(4):518–21. https://doi.org/10.1099/jmm.0.060236-0.PubMedCrossRef

Bonifaz, et al. Superficial mycoses associated with diaper dermatitis. Mycopathologia. 2016;181(9–10):671–9. https://doi.org/10.1007/s11046-016-0020-9.PubMedPubMedCentralCrossRef

Moyes DL, Wilson D, Richardson JP, Mogavero S, Tang SX, Wernecke J, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature. 2016;532(7597):64–8. https://doi.org/10.1038/nature17625.PubMedPubMedCentralCrossRef

Naglik JR, Gaffen SL, Hube B. Candidalysin: discovery and function in Candida albicans infections. Curr Opin Microbiol. 2019;52:100–9. https://doi.org/10.1016/j.mib.2019.06.002.PubMedPubMedCentralCrossRef

10.

Ho J, Yang X, Nikou SA, Kichik N, Donkin A, Ponde NO, et al. Candidalysin activates innate epithelial immune responses via epidermal growth factor receptor. Nat Commun. 2019;10(1):2297. https://doi.org/10.1038/s41467-019-09915-2.PubMedPubMedCentralCrossRef

11.

Swidergall M, Khalaji M, Solis NV, Moyes DL, Drummond RA, Hube B, et al. Candidalysin is required for neutrophil recruitment and virulence during systemic Candida albicans infection. J Infect Dis. 2019;220(9):1477–88. https://doi.org/10.1093/infdis/jiz322.PubMedPubMedCentralCrossRef

12.

King J, Pana ZD, Lehrnbecher T, Steinbach WJ, Warris A. Recognition and clinical presentation of invasive fungal disease in neonates and children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S12–21. https://doi.org/10.1093/jpids/pix053.PubMedPubMedCentralCrossRef

13.

Smolinski KN, Shah SS, Honig PJ, Yan AC. Neonatal cutaneous fungal infections. Curr Opin Pediatr. 2005;17(4):486–93. https://doi.org/10.1097/01.mop.0000171320.91677.55.PubMedCrossRef

14.

•• Kaufman DA, Coggins SA, Zanelli SA, Weitkamp JH. Congenital cutaneous candidiasis: prompt systemic treatment is associated with improved outcomes in neonates. Clin Infect Dis. 2017;64(10):1387–95. https://doi.org/10.1093/cid/cix119(A complete description of the clinical picture, risk factors, evolution, and recommendations about treatment for congenital cutaneous candidiasis are detailed).PubMedCrossRef

15.

Rex, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30(4):662–78. https://doi.org/10.1086/313749.PubMedCrossRef

16.

Marty M, Bourrat E, Vaysse F, Bonner M, Bailleul-Forestier I. Direct microscopy: a useful tool to diagnose oral candidiasis in children and adolescents. Mycopathologia. 2015;180(5–6):373–7. https://doi.org/10.1007/s11046-015-9933-y.PubMedCrossRef

17.

Arenas R, Torres E. Candidosis (candidiasis). In: Serrano H, editor. Micología médica ilustrada. 6th ed. México: McGraw-Hill; 2019. p. 249–69.

18.

Sanghvi R, Siddik D, Hullah E, Shah T, Carey B. Chronic mucocutaneous candidiasis: a rare diagnosis in paediatric dentistry. Br J Oral Maxillofac Surg. 2020;58:708–10. https://doi.org/10.1016/j.bjoms.2020.03.025.PubMedCrossRef

19.

Green L, Dolen WK. Chronic candidiasis in children. Curr Allergy Asthma Rep. 2017;17(5):31. https://doi.org/10.1007/s11882-017-0699-9.PubMedCrossRef

20.

•• Matsubara VH, Bandara HM, Mayer MP, Samaranayake LP. Probiotics as antifungals in mucosal candidiasis. Clin Infect Dis. 2016;62(9):1143–53. https://doi.org/10.1093/cid/ciw038(The evidence of the benefits of using probiotics in candidiasic infections and general health with in vivo or in vitro studies is detailed).PubMedCrossRef

21.

Admani S, Jinna S, Friedlander S, Sloan B. Cutaneous infectious diseases: kids are not just little people. Clin Dermatol. 2015;33:657–71. https://doi.org/10.1016/j.clindermatol.2015.09.008.PubMedCrossRef

22.

Zampella JG, Kwatra SG, Blanck J, Cohen B. Tinea in tots: cases and literature review of oral antifungal treatment of tinea capitis in children under 2 years of age. J Pediatr. 2017;183:12–18.e3. https://doi.org/10.1016/j.jpeds.2016.12.042.PubMedCrossRef

23.

Fremerey C, Nenoff P. Tinea capitis in a newborn. N Engl J Med. 2018;378(21):2022. https://doi.org/10.1056/NEJMicm1711862.PubMedCrossRef

24.

Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345:e4380. https://doi.org/10.1136/bmj.e4380.PubMedCrossRef

25.

Rebollo N, López-Barcenas A, Arenas R. Tiña de la cabeza. Actas Dermosifiliogr. 2008;99:91–100. https://doi.org/10.1016/S0001-7310(08)74630-1.PubMedCrossRef

26.

Amorim F, Sidta M, Beatriz C. Tinea capitis in street-children of Maputo, Mozambique. J Mycol Med. 2001;11:92–4.

27.

Ginter-Hanselmayer G, Weger W, Ilkit M, Smolle J. Epidemiology of tinea capitis in Europe: current state and changing patterns. Mycoses. 2007;50(Suppl 2):6–13. https://doi.org/10.1111/j.1439-0507.2007.01424.x.PubMedCrossRef

28.

Romano C, Massai L, Difonzo EM. Dermatophytosis due to Trichophyton violaceum in Tuscany from 1985 to 1997. Mycoses. 2000;43:169–72. https://doi.org/10.1046/j.1439-0507.2000.00567.x.PubMedCrossRef

29.

Cuetara MS, Del Palacio A, Pereiro M, Noriega AR. Prevalence of undetected tinea capitis in a prospective school survey in Madrid: emergence of new causative fungi. Brit J Dermatol. 1998;138:658–60. https://doi.org/10.1046/j.1365-2133.1998.02181.x.CrossRef

30.

Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med. 1999;153:483–6. https://doi.org/10.1001/archpedi.153.5.483.PubMedCrossRef

31.

Mayser P, Nenoff P, Reinel D, Abeck D, Brasch J, Daeschlein G, et al. S1 guidelines: tinea capitis. J German Soc Dermatol. 2019;18:161–79. https://doi.org/10.1111/ddg.14026.CrossRef

32.

Klatte J, Van der Beek N, Kemperman P. 100 years of Wood’s lamp revised. JEADV. 2015;29:842–7. https://doi.org/10.1111/jdv.12860.PubMedCrossRef

33.

Waskiel-Burnat A, Rakowska A, Sikora M, Ciechanowicz P, Olszewska M, Rudnicka L. Trichoscopy of tinea capitis: a systematic review. Dermatol Ther Heidelb. 2020;10:43–52. https://doi.org/10.1007/s13555-019-00350-1.PubMedPubMedCentralCrossRef

34.

Higgins EM, Fuller LC, Smith CH. Guidelines for the management of tinea capitis. British Association of Dermatologists. Br J Dermatol. 2000;143:53–8. https://doi.org/10.1046/j.1365-2133.2000.03530.x.PubMedCrossRef

35.

Bonifaz A, Isa-Isa R, Araiza J, Cruz C, Hernández MA, Ponce RM. Cytobrush-culture method to diagnose tinea capitis. Mycopathologia. 2007;163:309–13. https://doi.org/10.1007/s11046-007-9019-6.PubMedCrossRef

36.

Verrier J, Monod M. Diagnosis of dermatophytosis using molecular biology. Mycopathologia. 2017;182(1–2):193–202. https://doi.org/10.1007/s11046-016-0038-z.PubMedCrossRef

37.

Sugita T, Shiraki Y, Hiruma M. Real-time PCR TaqMan assay for detecting Trichophyton tonsurans, a causative agent of tinea capitis, from hairbrushes. Med Mycol. 2006;44:579–81. https://doi.org/10.1080/13693780600717153.PubMedCrossRef

38.

Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011;64:663–70. https://doi.org/10.1016/j.jaad.2010.02.048.PubMedCrossRef

39.

Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. J Drugs Dermatol. 2008;7(4):369–72.PubMed

40.

Gupta AK, Drummond-Main C. Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. Pediatr Dermatol. 2013;30:1–6. https://doi.org/10.1111/j.1525-1470.2012.01866.x.PubMedCrossRef

41.

• Bar J, Samuelov L, Sprecher E, Mashiah J. Griseofulvin vs terbinafine for paediatric tinea capitis: when and for how long. Mycoses. 2019;62:949–53. https://doi.org/10.1111/myc.12970(This article shows the efficacy of both medications).PubMedCrossRef

42.

Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016;5:Cd004685. https://doi.org/10.1002/14651858.CD004685.pub3.CrossRef

43.

•• Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children: an abridged Cochrane Review. J Am Acad Dermatol. 2017;76(2):368–74. https://doi.org/10.1016/j.jaad.2016.08.061(This article is an update of the original review showing the efficacy of griseofulvin and terbinafine in tinea capitis in children).PubMedCrossRef

44.

Hawkins D, Smidt A. Superficial fungal infections in children. Pediatr Clin N Am. 2014;61:443–55. https://doi.org/10.1016/j.pcl.2013.12.003.CrossRef

45.

Hussain I, Muzaffar F, Rashid T, Ahmad TJ, Jahangir M, Haroon TS. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Med Mycol. 1999;37:97–09.PubMedCrossRef

46.

Kelly B. Superficial fungal infections. Pediatr Rev. 2012;33:e22–37. https://doi.org/10.1542/pir.33-4-e22.PubMedCrossRef

47.

Nara Frota A, Canato M, Arake Zanatta D, et al. Majocchi granuloma on a child’s face. Dermatol Online J. 2018;24(12):13.

48.

Soligo Kanaan IC, Kawa Kac B, Mosca de Cerqueira AM, et al. Majocchi’s granuloma- case report. Am Bras Dermatol. 2015;90(2):251–3. https://doi.org/10.1590/abd1806-4841.20153115.CrossRef

49.

Wen-Wei F, Hsiu-Chao C, Hung-Chi C. Majocchi’s granuloma in a 3-year-old boy. Pediatr Infect Dis J. 2006;25:658–9. https://doi.org/10.1097/01.inf.0000224312.87417.fc.CrossRef

50.

Sahoo A, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7(2):77–86. https://doi.org/10.4103/2229-5178.178099.PubMedPubMedCentralCrossRef

51.

El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;(8):Art. No.: CD009992. https://doi.org/10.1002/14651858.CD009992.pub2.

52.

Kaur R, Kashyap B, Makkar R. Evaluation of clinicomycological aspects of onychomycosis. Indian J Dermatol. 2008;53(4):174–8. https://doi.org/10.4103/0019-5154.44788.PubMedPubMedCentralCrossRef

53.

Vásquez-del Mercado E, Arenas R. Onicomicosis en niños. Estudio retrospectivo de 233 casos mexicanos [Onychomycosis among children. A retrospective study of 233 Mexican cases]. Gac Med Mex. 2008;144(1):7–10.PubMed

54.

Bonifaz A, Saúl A, Mena C, Valencia A, Paredes V, Fierro L, et al. Dermatophyte onychomycosis in children under 2 years of age: experience of 16 cases. J Eur Acad Dermatol Venereol. 2007;21(1):115–7. https://doi.org/10.1111/j.1468-3083.2006.01802.x.PubMedCrossRef

55.

Chu DH, Rubin AI. Diagnosis and management of nail disorders in children. Pediatr Clin N Am. 2014;61(2):293–308. https://doi.org/10.1016/j.pcl.2013.11.005.CrossRef

56.

Gupta AK, Mays RR, Versteeg SG, Shear NH, Friedlander SF. Onychomycosis in children: safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35(5):552–9. https://doi.org/10.1111/pde.13561.PubMedCrossRef

57.

Rodríguez-Pazos L, Pereiro-Ferreirós MM, Pereiro M Jr, Toribio J. Onychomycosis observed in children over a 20-year period. Mycoses. 2011;54(5):450–3. https://doi.org/10.1111/j.1439-0507.2010.01878.x.PubMedCrossRef

58.

Lange M, Roszkiewicz J, Szczerkowska-Dobosz A, Jasiel-Walikowska E, Bykowska B. Onychomycosis is no longer a rare finding in children. Mycoses. 2006;49(1):55–9. https://doi.org/10.1111/j.1439-0507.2005.01186.x.PubMedCrossRef

59.

Carvalho VO, Vicente VA, Werner B, et al. Onychomycosis by Fusarium oxysporum probably acquired in utero. Med Mycol Case Rep. 2014;6:58–61. Published 2014 Oct 5. https://doi.org/10.1016/j.mmcr.2014.09.005.PubMedPubMedCentralCrossRef

60.

Peña-Penabad C, García-Silva J, Almagro M, del Pozo J, Fonseca E. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol. 2001;15(1):51–3. https://doi.org/10.1046/j.1468-3083.2001.00182.x.PubMedCrossRef

61.

García-Romero MT, Lopez-Aguilar E, Arenas R. Onychomycosis in immunosuppressed children receiving chemotherapy [published correction appears in Pediatr Dermatol. 2014 Nov-Dec;31(6):759]. Pediatr Dermatol. 2014;31(5):618–20. https://doi.org/10.1111/pde.12030.PubMedCrossRef

62.

García-Romero MT, Granados J, Vega-Memije ME, Arenas R. Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives. Actas Dermosifiliogr. 2012;103(1):59–62. https://doi.org/10.1016/j.adengl.2011.03.017.PubMedCrossRef

63.

Alvarado Z, Pereira C. Fungal diseases in children and adolescents in a referral centre in Bogota, Colombia. Mycoses. 2018;61(8):543–8. https://doi.org/10.1111/myc.12774.PubMedCrossRef

64.

Ploysangam T, Lucky AW. Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. J Am Acad Dermatol. 1997;36(1):29–32. https://doi.org/10.1016/s0190-9622(97)70321-9.PubMedCrossRef

65.

Moreno G, Arenas R. Other fungi causing onychomycosis. Clin Dermatol. 2010;28(2):160–3. https://doi.org/10.1016/j.clindermatol.2009.12.009.PubMedCrossRef

66.

Gupta AK, Skinner AR, Baran R. Onychomycosis in children: an overview. J Drugs Dermatol. 2003;2(1):31–4.PubMed

67.

Wilsmann-Theis D, Sareika F, Bieber T, Schmid-Wendtner MH, Wenzel J. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol. 2011;25(2):235–7. https://doi.org/10.1111/j.1468-3083.2010.03704.x.PubMedCrossRef

68.

Haghani I, Shokohi T, Hajheidari Z, Khalilian A, Aghili SR. Comparison of diagnostic methods in the evaluation of onychomycosis. Mycopathologia. 2013;175(3–4):315–21. https://doi.org/10.1007/s11046-013-9620-9.PubMedCrossRef

69.

Feldstein S, Totri C, Friedlander SF. Antifungal therapy for onychomycosis in children. Clin Dermatol. 2015;33(3):333–9. https://doi.org/10.1016/j.clindermatol.2014.12.010.PubMedCrossRef

70.

Eichenfield LF, Friedlander SF. Pediatric onychomycosis: the emerging role of topical therapy. J Drugs Dermatol. 2017;16(2):105–9.PubMed

71.

Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol. 2013;30(3):316–22. https://doi.org/10.1111/pde.12064.PubMedCrossRef

72.

Bonifaz A, Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr Dermatol. 2000;17(4):310–4. https://doi.org/10.1046/j.1525-1470.2000.01761.x.PubMedCrossRef

73.

Patel D, Castelo-Soccio LA, Rubin AI, Streicher JL. Laboratory monitoring during systemic terbinafine therapy for pediatric Onychomycosis. JAMA Dermatol. 2017;153(12):1326–7. https://doi.org/10.1001/jamadermatol.2017.4483.PubMedPubMedCentralCrossRef

74.

Gupta AK, Paquet M. Systemic antifungals to treat onychomycosis in children: a systematic review. Pediatr Dermatol. 2013;30(3):294–302. https://doi.org/10.1111/pde.12048.PubMedCrossRef

75.

Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5–6):327–30. https://doi.org/10.1080/09546630500420183.PubMedCrossRef

76.

Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494–502. https://doi.org/10.1016/j.jaad.2011.02.038.PubMedCrossRef

77.

Yamada T, Maeda M, Alshahni MM, Tanaka R, Yaguchi T, Bontems O, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/AAC.00115-17.

78.

Hiruma J, Kitagawa H, Noguchi H, Kano R, Hiruma M, Kamata H, et al. Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. J Dermatol. 2019;46:351–3. https://doi.org/10.1111/1346-8138.14809.PubMedCrossRef

79.

Saunte DML, Hare RK, Jørgensen KM, Jørgensen R, Deleuran M, Zachariae CO, et al. Emerging terbinafine resistance in Trichophyton: clinical characteristics, squalene epoxidase gene mutations and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019;63:e01126-19. https://doi.org/10.1128/AAC.01126-19.PubMedPubMedCentralCrossRef

80.

Monod M. Antifungal resistance in dermatophytes: emerging problem and challenge for the medical community. J Mycol Méd. 2019;29:283–4. https://doi.org/10.1016/j.mycmed.2019.100913.PubMedCrossRef

81.

Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103–255. https://doi.org/10.1016/j.fgb.2019.103255.CrossRef

82.

Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62:227–36. https://doi.org/10.4103/ijd.IJD_206_17.PubMedPubMedCentralCrossRef

83.

Friedman D, Schwartz I. Emerging fungal infections: new patients, new patterns, and new pathogens. Journal of Fungi. 2019;5:67. https://doi.org/10.3390/jof5030067.PubMedCentralCrossRef

84.

Ebert A, Monod M, Salamin K, Burmester A, Uhrlaß S, Wiegand C, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63(7):717–28. https://doi.org/10.1111/myc.13091.PubMedCrossRef

85.

Kronborg Andersen L, Cavling Arendrup M, Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr Dermatol. 2018;35:1–2. https://doi.org/10.1111/pde.13411.CrossRef

86.

Gupta A, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin. 2003;21:413–29. https://doi.org/10.1016/S0733-8635(03)00039-1.PubMedCrossRef

87.

Saunte D, Gaitanis G, James-Hay R. Malassezia-associated skin diseases, the use of diagnostics and treatment. Front Cell Infect Microbiol. 2020;10:112. https://doi.org/10.3389/fcimb.2020.00112.PubMedPubMedCentralCrossRef

88.

Terragni L, Lasagni A, Oriani A, Gelmetti C. Pityriasis versicolor in the pediatric age. Pediatr Dermatol. 1991;8(1):9–12. https://doi.org/10.1111/j.1525-1470.1991.tb00831.x.PubMedCrossRef

89.

Cullen SI. Age of patients with pityriasis versicolor. J Am Acad Dermatol. 1983;9:464–5.PubMedCrossRef

90.

Kallini J, Riaz F, Khachemoune A. Tinea versicolor in dark-skinned individuals. Int J Dermatol. 2014;53(2):137–41. https://doi.org/10.1111/ijd.12345.PubMedCrossRef

91.

Maymone M, Watchmaker J, Dubiel M, Wirya S, Shen L, Vashi N. Common skin disorders in pediatric skin of color. J Pediatr Health Care. 2019;33:727–37. https://doi.org/10.1016/j.pedhc.2019.04.019.PubMedCrossRef

92.

Mendez-Tovar L. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol. 2009;28(2):185–9. https://doi.org/10.1016/j.clindermatol.2009.12.015.CrossRef

93.

•• Jubert E, Martín-Santiago A, Bernardino M, Bauzá A. Neonatal pityriasis versicolor. Pediatr Infect Dis J. 2015;34:329–30. https://doi.org/10.1097/INF.0000000000000568(This article details specific characteristics of pityriasis versicolor in the neonatal period).PubMedCrossRef

94.

Allegue F, Fachal C, González-Villas D, Zulaica A. Atrophying pityriasis versicolor. Act Dermosifiliogr. 2018;109(5):455–7. https://doi.org/10.1016/j.adengl.2018.04.011.CrossRef

95.

•• Stephen J, Magro C. Atrophying pityriasis versicolor as an idiosyncratic T cell mediated response to Malassezia: a case series. J Am Acad Dermatol. 2017;76:730–5. https://doi.org/10.1016/j.jaad.2016.08.062(The authors describe this rare variant we must be familiar with in order to understand the underlying pathophysiology and differentiate it from other entities).CrossRef

96.

• Hu S, Bigby M. Pityriasis versicolor. A systematic review of interventions. Arch Dermatol. 2010;146(10):1132–14. https://doi.org/10.1001/archdermatol.2010.259(There is a wide range of treatments for PV. (This article details the available medications, dosages, presentations, and their adverse effects).PubMedCrossRef

97.

Kaur I, Jakhar D, Singai A. Dermoscopy in the evaluation of pityriasis versicolor: a cross sectional study. Indian Dermatol Online J. 2019;10(6):682–5. https://doi.org/10.4103/idoj.IDOJ_502_18.PubMedPubMedCentralCrossRef

98.

Pantazidou A, Tebruegge M. Recurrent tinea versicolor: treatment with itraconazole or fluconazole? Arch Dis Child. 2007;92(11):1040–2. https://doi.org/10.1136/adc.2007.124958.PubMedCrossRef

99.

•• Bakr E, Abdo H, Abd-Elaziz H, Abd-Elrazek H, Amer M. Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: a randomized clinical study. Dermatol Ther. 2020:e13319. https://doi.org/10.1111/dth.13319(This combination treatment was found to be effective to decrease scale and itch, and achieve mycological cure as well as patient satisfaction).

100.

Alberdi E, Gómez C. Successful treatment of Pityriasis Versicolor by photodynamic therapy mediated by methylene blue. Photodermatol Photoimmunol Photomed. 2020;00:1–5. https://doi.org/10.1111/phpp.12555.CrossRef

101.

Mahajan VK. Sporotrichosis: an overview and therapeutic options. Dermatol Res Pract. 2014;2014:272376–13. https://doi.org/10.1155/2014/272376.PubMedPubMedCentralCrossRef

102.

Arenas R. Sporotrichosis. In: Arenas R, Estrada R, editors. Tropical dermatology. Georgetown: Landes Bioscience; 2001.CrossRef

103.

Lyon GM, Zurita S, Casquero J, Holgado W, Guevara J, Brandt ME, et al. Sporotrichosis in Peru Investigation Team. Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru. Clin Infect Dis. 2003;36:34–9. https://doi.org/10.1086/345437 Epub 2002 Dec 12.PubMedCrossRef

104.

Ramírez Soto MC. Sporotrichosis: The story of an endemic region in Peru over 28 years (1985 to 2012). PLoS One. 2015;10(6):e0127924 Published 2015 Jun 1. https://doi.org/10.1371/journal.pone.0127924.PubMedPubMedCentralCrossRef

105.

Ramos-e-Silva M, Vasconcelos C, Carneiro S, Cestari T. Sporotrichosis. Clin Dermatol. 2007;25:181–7. https://doi.org/10.1016/j.clindermatol.2006.05.006.PubMedCrossRef

106.

•• Bonifaz A, Saúl A, Paredes-Solis V, Fierro L, Rosales A, Palacios C, et al. Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. Pediatr Dermatol. 2007;24(4):369–72. https://doi.org/10.1111/j.1525-1470.2007.00452.x(This paper shows clearly the clinical spectrum for sporotrichosis in children).PubMedCrossRef

107.

McGuinness SL, Boyd R, Kidd S, McLeod C, Krause VL, Ralph AP. Epidemiological investigation of an outbreak of cutaneous sporotrichosis, Northern Territory. Australia BMC Infect Dis. 2016;16(1):16. https://doi.org/10.1186/s12879-016-1338-0 PMID: 26758905.PubMedCrossRef

108.

Pappas PG, Tellez I, Deep AE, Nolasco D, Holgado W, Bustamante B. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis. 2000;30(1):65–70. https://doi.org/10.1086/313607.PubMedCrossRef

109.

da Rosa AC, Scroferneker ML, Vettorato R, Gervini RL, Vettorato G, Weber A. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol. 2005;52(3 Pt 1):451–9. https://doi.org/10.1016/j.jaad.2004.11.046.PubMedCrossRef

110.

•• Tirado-Sánchez A, Bonifaz A. Sporotrichosis in children: an update. Curr Fungal Infect Rep. 2016;10:107–16. https://doi.org/10.1007/s12281-016-0259-0(This article is an excellent review of sporotrichosis in children).CrossRef

111.

Sanchotene KO, Madrid IM, Klafke GB, Bergamashi M, Della Terra PP, Rodrigues AM, et al. Sporothrix brasiliensis outbreaks and the rapid emergence of feline sporotrichosis. Mycoses. 2015;58(11):652–8. PMID: 26404561. https://doi.org/10.1111/myc.12414.PubMedCrossRef

112.

Gremião ID, Menezes RC, Schubach TM, Figueiredo AB, Cavalcanti MC, Pereira SA. Feline sporotrichosis: epidemiological and clinical aspects. Med Mycol. 2015;53(1):15–21. https://doi.org/10.1093/mmy/myu061 Epub 2014 Dec 4.PubMedCrossRef

113.

Barros MB, Costa DL, Schubach TM, do Valle AC, Lorenzi NP, Teixeira JL, et al. Endemic of zoonotic sporotrichosis: profile of cases in children. Pediatr Infect Dis J. 2008;27(3):246–50. https://doi.org/10.1097/INF.0b013e31815bf309.PubMedCrossRef

114.

Orofino-Costa R, Macedo PM, Rodrigues AM, Bernardes-Engemann AR. Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics. An Bras Dermatol. 2017;92(5):606–20. https://doi.org/10.1590/abd1806-4841.2017279.PubMedPubMedCentralCrossRef

115.

Takenaka M, Yoshizaki A, Utani A, Nishimoto K. A survey of 165 sporotrichosis cases examined in Nagasaki prefecture from 1951 to 2012. Mycoses. 2014;57(5):294–8. https://doi.org/10.1111/myc.12158 Epub 2013 Nov 28.PubMedCrossRef

116.

Verma S, Verma GK, Singh G, Kanga A, Shanker V, Singh D, et al. Sporotrichosis in sub-Himalayan India. PLoS Negl Trop Dis. 2012;6(6):e1673. https://doi.org/10.1371/journal.pntd.0001673 Epub 2012 Jun 12.PubMedPubMedCentralCrossRef

117.

Rippon JW. Sporotrichosis. In: Rippon JW, editor. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. Philadelphia: WB Saunders; 1988. p. 325–52.

118.

Morris-Jones R. Sporotrichosis. Clin Exp Dermatol. 2002;27:427–31. https://doi.org/10.1046/j.1365-2230.2002.01087.x.PubMedCrossRef

119.

Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(10):1255–65. https://doi.org/10.1086/522765.PubMedCrossRef

120.

Yamada K, Zaitz C, Framil VM, Muramatu LH. Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in São Paulo State, Brazil. Rev Inst Med Trop Sao Paulo. 2011;53(2):89–93. https://doi.org/10.1590/s0036-46652011000200006.PubMedCrossRef

121.

Vásquez-del-Mercado E, Arenas R, Padilla-Desgarenes C. Sporotrichosis. Clin Dermatol. 2012;30(4):437–43. https://doi.org/10.1016/j.clindermatol.2011.09.017.PubMedCrossRef

122.

•• Brito AC, Bittencourt MJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. An Bras Dermatol. 2018;93(4):495–506. https://doi.org/10.1590/abd1806-4841.20187321(The article provides an update of epidemiological, clinical, diagnostic, and therapeutic features.).PubMedPubMedCentralCrossRef

123.

McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983;8(1):1–16. https://doi.org/10.1016/s0190-9622(83)70001-0.PubMedCrossRef

124.

Rubin HA, Bruce S, Rosen T, McBride ME. Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis. J Am Acad Dermatol. 1991;25(5 Pt 2):951–4. https://doi.org/10.1016/0190-9622(91)70292-a.PubMedCrossRef

125.

Arenas R. Chromoblastomycosis. In: Arenas R, Estrada R, editors. Tropical dermatology. Georgetown, TX: Landes Bioscience; 2001.CrossRef

126.

Krzyściak PM, Pindycka-Piaszczyńska M, Piaszczyński M. Chromoblastomycosis. Postepy Dermatol Alergol. 2014;31(5):310–21. https://doi.org/10.5114/pdia.2014.40949.PubMedPubMedCentralCrossRef

127.

Naka W, Harada T, Nishikawa T, Fukushiro R. A case of chromoblastomycosis: with special reference to the mycology of the isolated Exophiala jeanselmei. Mykosen. 1986;29(10):445–52. https://doi.org/10.1111/j.1439-0507.1986.tb03943.x.PubMedCrossRef

128.

Barba-Gómez JF, Mayorga J, McGinnis MR, González-Mendoza A. Chromoblastomycosis caused by Exophiala spinifera. J Am Acad Dermatol. 1992;26(2 Pt 2):367–70. https://doi.org/10.1016/0190-9622(92)70058-n.PubMedCrossRef

129.

Padhye AA, Hampton AA, Hampton MT, Hutton NW, Prevost-Smith E, Davis MS. Chromoblastomycosis caused by Exophiala spinifera. Clin Infect Dis. 1996;22(2):331–5. https://doi.org/10.1093/clinids/22.2.331.PubMedCrossRef

130.

Tomson N, Abdullah A, Maheshwari MB. Chromomycosis caused by Exophiala spinifera. Clin Exp Dermatol. 2006;31(2):239–41. https://doi.org/10.1111/j.1365-2230.2005.02006.x.PubMedCrossRef

131.

• Pérez-Blanco M, Hernández Valles R, García-Humbría L, Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the Falcón State, Venezuela. Med Mycol. 2006;44(5):467–71. https://doi.org/10.1080/13693780500543238(This article shows the importance of early diagnosis and intervention in children with chromoblastomycosis).PubMedCrossRef

132.

Agarwal R, Singh G, Ghosh A, Verma KK, Pandey M, Xess I. Chromoblastomycosis in India: review of 169 cases. PLoS Negl Trop Dis. 2017;11(8):e0005534. Published 2017 Aug 3. https://doi.org/10.1371/journal.pntd.0005534.PubMedPubMedCentralCrossRef

133.

•• Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30(1):233–76. https://doi.org/10.1128/CMR.00032-16(This article is an excellent review of chromoblastomycosis).PubMedCrossRef

134.

Navarrete MR, Arenas R, Estrada VFM, Diéguez CEA, Mayorga J, Bonifaz A, et al. Cromoblastomicosis en México. Revisión de 603 casos en siete décadas. Dermatologia CMQ. 2014;12:87–93.

135.

Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol. 1989;27(3):181–5. https://doi.org/10.1080/02681218980000241.PubMedCrossRef

136.

Pradeepkumar NS, Joseph NM. Chromoblastomycosis caused by Cladophialophora carrionii in a child from India. J Infect Dev Ctries. 2011;5(7):556–60. Published 2011 Jul 27. https://doi.org/10.3855/jidc.1392.PubMedCrossRef

137.

Bonifaz A, Carrasco-Gerard E, Saúl A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44(1–2):1–7. https://doi.org/10.1046/j.1439-0507.2001.00613.x.PubMedCrossRef

138.

Londero AT, Ramos CD. Chromomycosis: a clinical and mycologic study of thirty-five cases observed in the hinterland of Rio Grande do Sul, Brazil. Am J Trop Med Hyg. 1976;25(1):132–5. https://doi.org/10.4269/ajtmh.1976.25.132.PubMedCrossRef

139.

Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol. 2005;53(6):931–54. https://doi.org/10.1016/j.jaad.2004.10.883.PubMedCrossRef

140.

Esterre P, Andriantsimahavandy A, Ramarcel ER, Pecarrere JL. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg. 1996;55(1):45–7. https://doi.org/10.4269/ajtmh.1996.55.45.PubMedCrossRef

141.

Esterre P, Andriantsimahavandy A, Raharisolo C. Histoire naturelle des chromoblastomycoses à Madagascar et dans l’Océan indien [natural history of chromoblastomycosis in Madagascar and the Indian Ocean] natural history of chromoblastomycosis in Madagascar and the [natural history of chromoblastomycosis in Madagascar and the Indian Ocean]. Bull Soc Pathol Exot. 1997;90(5):312–7.PubMed

142.

Iwatsu T, Takano M, Okamoto S. Auricular chromomycosis. Arch Dermatol. 1983;119(1):88–9.PubMedCrossRef

143.

Takase T, Baba T, Uyeno K. Chromomycosis. A case with a widespread rash, lymph node metastasis and multiple subcutaneous nodules. Mycoses. 1988;31(7):343–52. https://doi.org/10.1111/j.1439-0507.1988.tb04429.x.PubMedCrossRef

144.

Azulay RD, Serruya J. Hematogenous dissemination in chromoblastomycosis. Report of a generalized case. Arch Dermatol. 1967;95(1):57–60.PubMedCrossRef

145.

Gopal KVT, Ramani TV, Panda S, Laxmi PVBR. Disseminated chromoblastomycosis: diffuse truncal involvement with hematogenous spread. Int J Health Allied Sci. 2012;1(3):194±6. https://doi.org/10.4103/2278-344X.105087.CrossRef

146.

Torres E, Beristain JG, Lievanos Z, Arenas R. Chromoblastomycosis associated with a lethal squamous cell carcinoma. An Bras Dermatol. 2010;85(2):267–70. https://doi.org/10.1590/s0365-05962010000200025.PubMedCrossRef

147.

Sharma N, Marfatia YS. Genital elephantiasis as a complication of chromoblastomycosis: a diagnosis overlooked. Indian J Sex Transm Dis AIDS. 2009;30(1):43–5. https://doi.org/10.4103/0253-7184.55486.PubMedPubMedCentralCrossRef

148.

Caplan RM. Epidermoid carcinoma arising in extensive chromoblastomycosis. Arch Dermatol. 1968;97(1):38–41.PubMedCrossRef

149.

Foster HM, Harris TJ. Malignant change (squamous carcinoma) in chronic chromoblastomycosis. Aust N Z J Surg. 1987;57(10):775–7. https://doi.org/10.1111/j.1445-2197.1987.tb01260.x.PubMedCrossRef

150.

Oberto-Perdigón L, Romero H, Pérez-Blanco M, Apitz-Castro R. Inmunoanálisis enzimático (ELISA) en la evolución terapéutica de la cromoblastomicosis por Cladophialophora carrionii en el área endémica del Estado Falcón, Venezuela [an ELISA test for the study of the therapeutic evolution of chromoblastomycosis by Cladophialophora carrionii in the endemic area of Falcon State, Venezuela]. Rev Iberoam Micol. 2005;22(1):39–43. https://doi.org/10.1016/s1130-1406(05)70005-x.PubMedCrossRef

151.

Tsianakas A, Pappai D, Basoglu Y, Metze D, Tietz HJ, Luger TA, et al. Chromomycosis--successful CO2 laser vaporization. J Eur Acad Dermatol Venereol. 2008;22(11):1385–6. https://doi.org/10.1111/j.1468-3083.2008.02649.x.PubMedCrossRef

152.

Hira K, Yamada H, Takahashi Y, Ogawa H. Successful treatment of chromomycosis using carbon dioxide laser associated with topical heat applications. J Eur Acad Dermatol Venereol. 2002;16(3):273–5. https://doi.org/10.1046/j.1468-3083.2002.00479.x.PubMedCrossRef

153.

Lyon JP, Pedroso e Silva Azevedo C de M, Moreira LM, de Lima CJ, de Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia. 2011;172(4):293–7. https://doi.org/10.1007/s11046-011-9434-6.PubMedCrossRef

154.

Yang Y, Hu Y, Zhang J, Li X, Lu C, Liang Y, et al. A refractory case of chromoblastomycosis due to Fonsecaea monophora with improvement by photodynamic therapy. Med Mycol. 2012;50(6):649–53. https://doi.org/10.3109/13693786.2012.655258.PubMedCrossRef

155.

Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31(11):805–12. https://doi.org/10.1111/j.1365-4362.1992.tb04252.x.PubMedCrossRef

156.

Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988;544:504–16. https://doi.org/10.1111/j.1749-6632.1988.tb40448.x.PubMedCrossRef

157.

Bonifaz A, Saúl A, Paredes-Solis V, Araiza J, Fierro-Arias L. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat. 2005;16(1):47–51. https://doi.org/10.1080/09546630410024538.PubMedCrossRef

158.

Tanuma H, Hiramatsu M, Mukai H, Abe M, Kume H, Nishiyama S, et al. Case report. A case of chromoblastomycosis effectively treated with terbinafine. Characteristics of chromoblastomycosis in the Kitasato region, Japan. Mycoses. 2000;43(1–2):79–83. https://doi.org/10.1046/j.1439-0507.2000.00548.x.PubMedCrossRef

159.

Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996;134(Suppl 46):33–40. https://doi.org/10.1111/j.1365-2133.1996.tb15658.x.PubMedCrossRef

160.

Azevedo Cde M, Marques SG, Resende MA, et al. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses. 2008;51(4):341–4. https://doi.org/10.1111/j.1439-0507.2007.01485.x.PubMedCrossRef

161.

de Sousa MG, Belda W Jr, Spina R, et al. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014;58(12):1734–7. https://doi.org/10.1093/cid/ciu168.PubMedCentralCrossRef

162.

•• Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016;16(1):100–12. https://doi.org/10.1016/S1473-3099(15)00359-X(This article is an excellent review of the topic).PubMedCrossRef

163.

Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg. 2004;98(1):3–11. https://doi.org/10.1016/s0035-9203(03)00009-9.PubMedCrossRef

164.

Fahal AH, Sabaa AH. Mycetoma in children in Sudan. Trans R Soc Trop Med Hyg. 2010;104(2):117–21. https://doi.org/10.1016/j.trstmh.2009.07.016.PubMedCrossRef

165.

Bonifaz A, Ibarra G, Saúl A, Paredes-Solis V, Carrasco-Gerard E, Fierro-Arias L. Mycetoma in children: experience with 15 cases. Pediatr Infect Dis J. 2007;26(1):50–2. https://doi.org/10.1097/01.inf.0000247108.86199.64.PubMedCrossRef

166.

Welsh O. Mycetoma in children. Mod Probl Paediatr. 1975;17:248–53.PubMed

167.

Pulikot AM, Bapat SS, Tolat S. Mycetoma of the sole. Ann Trop Paediatr. 2002;22(2):187–90. https://doi.org/10.1179/027249302125000931.PubMedCrossRef

168.

Tovar-Garza AP, Barrientos-García JG, Mayorga J. Micetoma en pacientes pediátricos. Reporte de 19 casos. Dermatol Rev Mex. 2015;59:189–94.

169.

Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Tropical Med Int Health. 2002;7(9):788–92. https://doi.org/10.1046/j.1365-3156.2002.00915.x.CrossRef

170.

Buot G, Lavalle P, Mariat F, Suchil P. Etude épidémiologique des mycétomes au Mexique. A propos de 502 cas [Epidemiologic study of mycetomas in Mexico. Apropos of 502 cases]. Bull Soc Pathol Exot Filiales. 1987;80(3):329–39.PubMed

171.

Khatri ML, Al-Halali HM, Fouad Khalid M, Saif SA, Vyas MC. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol. 2002;41(9):586–93. https://doi.org/10.1046/j.1365-4362.2002.01383.x.PubMedCrossRef

172.

Kwizera R, Bongomin F, Meya DB, Denning DW, Fahal AH, Lukande R. Mycetoma in Uganda: a neglected tropical disease. PLoS Negl Trop Dis. 2020;14(4):e0008240. Published 2020 Apr 29. https://doi.org/10.1371/journal.pntd.0008240.PubMedPubMedCentralCrossRef

173.

Hernandez-Hernandez F, Lopez-Martinez R, Mendez-Tovar LJ, Manzano-Gayosso P. Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones. Mycopathologia. 1995;132(2):79–85. https://doi.org/10.1007/BF01103779.PubMedCrossRef

174.

Emmanuel P, Dumre SP, John S, Karbwang J, Hirayama K. Mycetoma: a clinical dilemma in resource limited settings. Ann Clin Microbiol Antimicrob. 2018;17(1):35. Published 2018 Aug 10. https://doi.org/10.1186/s12941-018-0287-4.PubMedPubMedCentralCrossRef

175.

Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Clin Dermatol. 2007;25(2):195–202. https://doi.org/10.1016/j.clindermatol.2006.05.011.PubMedCrossRef

176.

Dieng MT, Niang SO, Diop B, Ndiaye B. Actinomycétomes au Sénégal. Etude de 90 cas [Actinomycetomas in Senegal: study of 90 cases]. Bull Soc Pathol Exot. 2005;98(1):18–20.PubMed

177.

Estrada R, Chávez-López G, Estrada-Chávez G, López-Martínez R, Welsh O. Eumycetoma. Clin Dermatol. 2012;30(4):389–96. https://doi.org/10.1016/j.clindermatol.2011.09.009.PubMedCrossRef

178.

Ameen M, Arenas R. Developments in the management of mycetomas. Clin Exp Dermatol. 2009;34(1):1–7. https://doi.org/10.1111/j.1365-2230.2008.03028.x.PubMedCrossRef

179.

Bonifaz A, Tirado-Sánchez A, Calderón L, et al. Mycetoma: experience of 482 cases in a single center in Mexico. PLoS Negl Trop Dis. 2014;8(8):e3102. Published 2014 Aug 21. https://doi.org/10.1371/journal.pntd.0003102.PubMedPubMedCentralCrossRef

180.

Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004;4(9):566–74. https://doi.org/10.1016/S1473-3099(04)01131-4.PubMedCrossRef

181.

Fahal AH. Mycetoma. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases. Principles, Pathogens and Practice. 3rd ed. Amsterdam: Elsevier; 2011. p. 565–568.

182.

López Martínez R, Méndez Tovar LJ, Lavalle P, Welsh O, Saúl A, Macotela RE. Epidemiología del micetoma en México: estudio de 2105 casos [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex. 1992;128(4):477–81.PubMed

183.

Fahal A, Suleiman S, Hay R. Mycetoma: the spectrum of clinical presentation. Tropical Medicine and Infectious Disease. 2018;3:97. https://doi.org/10.3390/tropicalmed3030097.PubMedCentralCrossRef

184.

Bonifaz A, González-Silva A, Albrandt-Salmerón A, Padilla Mdel C, Saúl A, Ponce RM. Utility of helical computed tomography to evaluate the invasion of actinomycetoma; a report of 21 cases. Br J Dermatol. 2008;158(4):698–704. https://doi.org/10.1111/j.1365-2133.2008.08435.x.PubMedCrossRef

185.

Lichon V, Khachemoune A. Mycetoma : a review. Am J Clin Dermatol. 2006;7(5):315–21. https://doi.org/10.2165/00128071-200607050-00005.PubMedCrossRef

Title: Skin Fungal Infections in Children: Diagnostic Challenges
Authors: Maria Teresa García-Romero
Gabriela Sánchez-Cardenas
Silvia Angélica Carmona-Cruz
Mónica Fernández-Sánchez
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Candidiasis
Candidiasis
Ringworm of the hair
Terbinafine
Onychomycosis
Published in: Current Fungal Infection Reports / Issue 4/2020
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-020-00407-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients

Cladorrhinum Bulbillosum Keratitis: Unraveling an Unusual Infection

Implementation of Effective Antifungal Stewardship in Cancer Patients—A Review of Current Evidence

Management of Mucormycosis

The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update

Invasive Fungal Keratitis as an Uncommon Form of Mucormycosis Leading to Endophthalmitis: Report of Two Cases and Literature Review

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage